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Abstract
Background: Matrix metalloproteinase-26 (MMP-26), one of the main mediators of extracellular matrix (ECM)
degradation, has been shown to exist in trophoblasts of human placenta and to play a role in trophoblast cell
invasion. However, little is known about the regulation of MMP-26 expression in human trophoblasts. Recently,
gonadotropin-releasing hormone I (GnRH I) and GnRH II have been shown to regulate the expression of MMP-2,
MMP-9/tissue inhibitor of metalloproteinases 1 (TIMP-1), and urokinase plasminogen activator (uPA)/plasminogen
activator inhibitor (PAI) in human trophoblasts, suggesting that these two hormones may work as paracrine and/or
autocrine regulators in modulating the activities of various protease systems at the feto-maternal interface. In this
study, we determined the regulatory effects of GnRH I and GnRH II on the expression of MMP-26 in human
immortalized cytotrophoblast-like cell line, B6Tert-1.
Methods: Real-time PCR was used to quantify mRNA levels of MMP-26 in human trophoblast-like cell line, B6Tert-1
and primary cultured cytotrophoblasts. Western blotting was used to characterize the expression of MMP-26 and
the phosphorylation of c-Jun NH2-terminal kinase (JNK) and extracellular signal-regulated kinase 1/2 (ERK1/2) in
B6Tert-1 cells after treatment with GnRH I and GnRH II.
Results: We found that GnRH I increased MMP-26 expression in B6Tert-1 cells after 12 h of treatment at both the
mRNA and protein level, while GnRH II increased MMP-26 expression beginning at 3 h of treatment. Treatment of
GnRH I at 1 nM resulted in maximal increase of MMP-26 mRNA and protein levels, whereas GnRH II treatment at a
concentration of 100 nM was required to induce maximal increase in MMP-26 expression. In addition, we
demonstrated that the activation of JNK, but not ERK1/2, was required for GnRH I and II-stimulated MMP-26
production in B6Tert-1 cells and primary cytotrophoblasts.
Conclusions: These novel findings indicated that GnRH I and II could up-regulate MMP-26 expression through the
JNK signaling pathway in human trophoblast-like/trophoblast cells.
Background
Trophoblast cell invasion is essential for successful
implantation and placentation. During the first trimester
of gestation, trophoblast cells proliferate, invade the
maternal decidua, and differentiate to form chorionic
villi, composed of an inner layer of cytotrophoblasts
(CTBs) and an outer layer of syncytiotrophoblasts [1,2].
A subpopulation of the proliferating CTBs subsequently
streams out of the syncytiotrophoblasts to form
mononuclear invasive extravillous cytotrophoblasts
(EVTs). These EVTs invade the maternal tissues and
penetrate the uterine arterioles, thereby ensuring a con-
tinuous blood supply to placenta and the developing
fetus [1,2]. These processes require the action of metal-
loproteinases (MMPs), a family of zinc-dependent pro-
teolytic enzymes that are the main mediators of
extracellular matrix (ECM) degradation [3].
MMP-26, also known as endometase or matrilysin-2,
was recently identified as the smallest member of MMP
family [4-6]. It is widely expressed in villous CTBs, syn-
cytiotrophoblasts and EVTs of human placenta [7].
MMP-26 exhibits wide substrate specificity in cleaving
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IV collagen, fibronectin, fibrinogen, vitronectin and gela-
tin [6,8]. The fact that most of these ECM components
are expressed in human villous trophoblasts [9] suggests
the involvement of MMP-26 in the degradation and
remodelling of ECM at the feto-maternal interface. In
addition, MMP-26 is able to process the lacent MMP-9,
to generate its active form [6,10]. Our previous studies
revealed that the spatiotemporal expression of MMP-26
was similar to that of MMP-9 in trophoblasts during the
first trimester [7,11], implicating that MMP-26 may also
indirectly contribute to ECM degradation through acti-
vation of proMMP-9 at the feto-maternal interface.
Recently, we found that overexpression of MMP-26
increases invasive capacity of human trophoblast cells in
vitro [12], suggesting the important role of MMP-26 in
trophoblast invasion. However, little is known about the
regulatory mechanism of MMP-26 expression in human
trophoblasts.
An increasing body of evidence has shown the extrapi-
tuitary functions of gonadotropin-releasing hormone I
(GnRH I) and the second mammalian form of this hor-
mone (GnRH II). In human placenta, GnRH I is widely
expressed among distinct subpopulations of trophoblasts
throughout gestation [13,14], while GnRH II expression
is restricted to mononuclear villous CTBs and EVTs
during the first trimester [13]. GnRH receptor (GnRHR)
is highly expressed in both CTBs and syncytiotropho-
blasts during early gestation [15]. Recently, GnRH I and
GnRH II have also been shown to regulate the expres-
sion of MMP-2, MMP-9/tissue inhibitor of metallopro-
teinases 1 (TIMP-1), and urokinase plasminogen
activator (uPA)/plasminogen activator inhibitor (PAI) in
human EVT cultures [16,17]. These observations suggest
the paracrine and/or autocrine regulatory roles of these
two hormones in modulating the activities of various
protease systems at the feto-maternal interface.
Based on previous findings from our laboratory and
o t h e r s ,w eh y p o t h e s i z e dt h a tG n R HIa n dG n R HI I
induce MMP-26 expression in trophoblast cells. In the
present study, we investigated the regulatory mechanism
of MMP-26 expression by GnRH I and GnRH II using
an in vitro experimental model of an immortalized
human cytotrophoblast-like cell line, B6Tert-1, which
has been established in our laboratory [18].
Methods
Materials
GnRH I and GnRH II native peptides were obtained
from Peninsula Laboratories, Inc. (San Carlos, CA).
ERK1/2 inhibitor (PD98059) and JNK inhibitor
(SP600125) were purchased from Sigma-Aldrich Corp.
(St. Louis, MO). PD98059 and SP600125 were dissolved
in DMSO. The antibodies specific against b-actin,
phospho-ERK1/2, phospho-JNK, total-ERK1/2 and total-
JNK were purchased from Cell Signaling Technology,
Inc. (Beverly, MA). The antibodies specific against
GnRH receptor were obtained from Lab Vision Corp.
(Fremont, CA). The polyclonal antibodies against MMP-
26 [5] are kind gifts from Dr. Qing-Xiang A. Sang of
Florida State University, Florida, USA.
Cell culture and treatment
Immortalized human cytotrophoblast-like B6Tert-1 cells
were cultured as described previously [18]. In brief, the
cells were cultured in collagen I (Cellmatrix Type I-A;
Institute of Biochemistry, Osaka, Japan)-coated flasks
with a defined serum-free medium [DMEM/F12 med-
ium (Gibco-Invitrogen, San Diego, CA) supplemented
with 10 ng/ml epidermal growth factor (EGF; Collabora-
tive Research, Lexington, MA) and 10 mg/ml insulin
(Sigma)]. Cells were incubated at 37°C in an atmosphere
of 5% CO2. To synchronize the cells, at least 18 hours
before each hormone treatment, concentration of EGF
in the culture medium was reduced from 10 ng/ml to 1
ng/ml and the concentration of insulin was decreased
from 10 mg/ml to 1 mg/ml. When reagents were dis-
solved in DMSO, the same concentration of DMSO was
added to medium for the control cells. After pretreat-
ment with inhibitors or vehicle [0.1% (vol/vol) DMSO]
for 30 minutes, the cells were treated with GnRH I or
GnRH II at concentration of 100 nM for a further 24
hours. Cells were collected at various time points fol-
lowing treatment with GnRH I or GnRH II.
Cells from the human choriocarcinoma cell line, JEG-
3, were purchased from American Type Culture Collec-
tion (ATCC, Rockville, MD). After thawing, the cells
were maintained in DMEM medium (Gibco-Invitrogen)
supplemented with antibiotics and 10% (vol/vol) heated-
inactivated fetal bovine serum (FBS; Gibco-Invitrogen).
Isolation of human primary cytotrophoblast (CTB) cells
Human chorionic villi tissues were obtained from
patients who underwent therapeutic termination of
pregnancy at 6~7 weeks of gestation. Informed consent
was provided by the patients, and the project received
prior approval from the local ethics committee. The
time of gestation was defined according to the first day
of the last menstrual period, and further morphological
examination by means of stereomicroscope. Primary
CTB cells were isolated from chorionic villi tissues as
previously described [19]. Briefly, tissues were minced
separately and digested with 0.25% (vol/vol) trypsin
(Sigma) and DNase I (Sigma). Next, the dispersed cells
were washed by DMEM/F12 medium (Gibco-Invitrogen)
and then filtered through a nylon sieve to remove the
gross villous core residues. The filtered cell suspension
was then slowly added to the top of a BSA gradient
[prepared by sequential addition of 3%, 2%, and 1% (wt/
vol) BSA in DMEM/F12 medium]. The cells were
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cells were collected from the bottom of the tube. The
purified CTB cells were cultured in defined serum free
medium and treated with GnRH I and GnRH II in the
absence or presence of inhibitors for 24 h.
RNA preparation and synthesis of first-strand cDNA
Total RNA was extracted from the B6Tert-1 or CTB
cells with TRIzol reagent (Invitrogen, San Diego, CA),
according to the manufacturer’s instructions. RNA was
subjected to DNase I digestion to avoid possible geno-
mic DNA contamination and then reverse transcribed
with oligo-dT primers and Superscript II reverse tran-
scriptase (Invitrogen).
Real-time PCR
The first-strand cDNA generated from the B6Tert-1 or
CTB cells served as a template for Real-time PCR using
the ABI PRISM 7000 sequence detection system (Perki-
nElmer Applied Biosystems, Foster City, CA) equipped
with a 96-well optical reaction plate. The primers used
for SYBR Green Real-time PCR were designed using the
PRIMER3 software and were as follows: human MMP-
26, 5’-TCC AGC AAG TGC AGA ATG GA-3’(forward)
and 5’-GGG CCC ACT GCC AGA AA-3’ (reverse);
human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), 5’-ATG GAA ATC CCA TCA CCA TCT T-
3’ (forward) and 5’-CGC CCC ACT TGA TTT TGG-3’
(reverse). The primer specificity for MMP-26 and
GAPDH was confirmed by running the PCR products
on a 2.0% agarose gel. Each Real-time PCR reaction
contained 12.5 μl SYBR Green ER qPCR SuperMix
(Invirogen), 2.5 μl of primer mixture (400 nm), and 10
μl of cDNA template [10% (vol/vol) RT reaction pro-
duct] under the following optimized conditions: 50°C
for 2 min followed by 95°C for 10 min and 40 cycles of
95°C for 15 sec and 55°C for 1 min. All PCR reactions
were performed in triplicate, with the mean being used
to determine mRNA levels. Relative mRNA expression
levels for MMP-26 were determined using the 2
-ΔΔCT
method [20] and normalized to the endogenous refer-
ence gene, GAPDH.
Western Blotting analysis
Total protein was isolated from B6Tert-1, JEG-3 or CTB
cells using lysis buffer (Cell Signaling). The protein
extracted from aT3-1 cells was kindly provided by Dr.
Peter C.K. Leung in University of British Columbia,
Canada. Total protein (30 μg) was run on 10% SDS-
polyacrylamide gels. After electrotransferring the protein
to the nitrocellulose membrane (Amersham Pharmacia
Biotech, Piscataway, NJ), the membrane was immuno-
blotted using specific primary antibodies for MMP-26,
GnRHR, phospho-ERK1/2 or phospho-JNK at 4°C over-
night. The signals were detected with horseradish perox-
idase-conjugated secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) for 1 hour and
visualized using the enhanced chemiluminescence sys-
tem (Amersham Pharmacia Biotech). After stripping, the
membranes were reprobed with b-actin, total-ERK1/2
and total-JNK antibodies, respectively. The relative den-
sity of MMP-26 was determined by normalization to the
density value of b-actin. The relative densities of phos-
phorylated forms of ERK1/2 and JNK were normalized
to total values of ERK1/2 and JNK. All densities were
analyzed using the Gel-Pro Analyzer (software version
4.0; United Bio., Marlton, NJ).
Transwell insert invasion assay
In vitro cell invasion was assayed by determining the
ability of cells to invade a synthetic basement mem-
brane. Briefly, 24-well fitted transwell inserts with mem-
branes (8- μm pore size, Millipore Corp, Bedford, MA)
were coated with growth factor reduced Matrigel (BD
Biosciences, Franklin, NJ) at a concentration of 200 μg/
mL and placed in a 24-well plate. B6Tert-1 cells at a
concentration of 2 × 10
4 were seeded in each insert
containing defined medium supplemented with 1 ng/ml
EGF and 1 mg/ml insulin and lower chambers were
loaded with defined medium containing 10 ng/ml EGF
and 10 mg/ml insulin. After incubating with or without
G n R HIo rG n R HI I( 1 0 0n M )f o r2 4h ,t h ec e l l sw e r e
then fixed and stained with crystal violet. Non-invaded
cells on the upper surface of the membrane were
removed using a cotton swab. The membranes were cut
from inserts and mounted onto glass slides. The number
of stained cells was counted, in at least 15 randomly
selected non-overlapping fields of the membranes, using
a light microscope.
Statistical analysis
Data were shown as the mean ± SEM of three individual
experiments performed in duplicate or triplicate. Statis-
tical analysis was carried out using one-way ANOVA
followed by Dunnett’s test, and differences were consid-
ered significant for P < 0.05. Representative images of
Western blot are shown.
Results
The characteristics of B6Tert-1 cells
The expression of GnRHR mRNA has been shown in
JEG-3 cells and first trimester CTB cells in primary cul-
ture [21]. To determine whether the GnRHR gene is
expressed in B6Tert-1 cells, levels of GnRHR protein
were assessed by Western blotting. As shown in Figure
1A, the expression of GnRHR protein was present in
both B6Tert-1 and JEG-3 cells. Mouse pituitary gonado-
trope aT3-1 cells, previously shown to express GnRHR
[22], were used as the positive control.
To characterize the invasiveness of B6Tert-1 cells in
response to GnRH I and II, cells treated with the native
peptides of these two subtypes of hormone were sub-
jected to invasion assay. The results indicated that
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B6Tert-1 cells, with the invasion index increasing to 1.6-
and 1.8-fold of control cultures, respectively (Figure 1B).
This observation is consistent with our previous report
that GnRH I and GnRH II promote EVT cell invasion
[23].
The expression of mRNA for MMP-2, MMP-9, MMP-
14, TIMP-1, TIMP-2 and TIMP-3 has been shown in
B6Tert-1 cells [18], while MMP-26 expression has yet to
be identified in this cell line. Western blotting analyses
revealed that the expression level of MMP-26 protein in
B6Tert-1 cells was comparable to that in the primary
CTB cells at 6-7 gestational weeks, but much higher
than that of human choriocarcinoma JEG-3 cells (Figure
1C). These results suggest that the B6Tert-1 cell line is
av a l u a b l ein vitro model to study the regulation of
GnRH I and II on MMP-26 expression in trophoblast-
like/trophoblast cell.
Time-dependent effects of GnRH I and GnRH II on MMP-
26 expression in B6Tert-1 cells
To investigate the regulatory effects of GnRH I and
GnRH II on MMP-26 expression in human cytotropho-
blasts, mRNA and protein levels were analyzed from
B6Tert-1 cells collected at various time points after
treatment with GnRH I or GnRH II (100 nM). Treat-
ment with GnRH I or GnRH II resulted in an increase
in MMP-26 production at mRNA or protein level in a
time-dependent manner (Figure 2), whereas the addition
of vehicle to the culture medium had no effect on the
expression of MMP-26 in B6Tert-1 cells at any of the
time points examined in this study (data not shown).
GnRH I increased the expression of MMP-26 mRNA
in B6Tert-1 cells during the interval of 12 h to 48 h
after treatment. The levels of MMP-26 mRNA at 48 h
were approximately 5 fold higher than that of the 0 h
(Figure 2A). A coordinate increase in the levels of
MMP-26 protein in these cell cultures was also observed
between 12 h and 48 h after GnRH I (Figure 2B).
GnRH II stimulated MMP-26 expression in B6Tert-1
cells in a manner differential to that of GnRH I: levels
for MMP-26 mRNA and protein increased at 3 h after
GnRH II treatment, peaked at 6 h, and gradually
decreased thereafter (Figure 2C and 2D). By 48 h after
treatment, MMP-26 mRNA expression decreased to a
level comparable to 0 h, while the protein level
remained significantly greater than those detected at 0 h
(Figure 2C and 2D).
Different dosage effects of GnRH I and GnRH II on MMP-
26 production in B6Tert-1 cells
To further determine the dosage effects of GnRHs on
MMP-26 production, B6Tert-1 cells were treated with
GnRH I or GnRH II at concentrations of 1, 10, 100 nM
and 1 μM) for 24 h. GnRH I significantly increased
MMP-26 mRNA and protein levels in B6Tert-1 cells at
all the hormone concentrations examined in these stu-
dies. The treatment of 1 nM GnRH I was sufficiently
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Figure 1 The characteristics of B6Tert-1 cells. A, Western blotting analyses show the expression of GnRH receptor (GnRHR) in JEG-3 and
B6Tert-1 cells. Mouse pituitary gonadotrope aT3-1 cells were used as the positive control. B, The B6Tert-1 cells were cultured in the presence of
100 nM GnRH I or GnRH II for 24 h, and their invasive capacities were analyzed by invasion assay. C, The expression of MMP-26 protein in JEG-3,
B6Tert-1, primary cultured cytotrophoblast (CTB) cells. The data derived from at least three independent sets of experiments (mean ± SEM; n ≥
3), and the statistic results are presented in the column graphs (*, P < 0.05 vs. control).
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(Figure 3A and 3B). GnRH II increased MMP-26 mRNA
and protein levels in B6Tert-1 cells in a dose-dependent
manner. A significant increase in MMP-26 expression
was first detected at concentration of 10 nM and the
highest expression of MMP-26 was observed in B6Tert-
1 cells in the presence of 100 nM GnRH II. However,
GnRH II at concentration of 1 μM was ineffective (Fig-
ure 3C and 3D).
Involvement of JNK pathway in GnRH I and II-induced
MMP-26 production
The mitogen-activated protein kinase (MAPK) signaling
cascade has been shown to mediate the action of GnRH
in human trophoblast cells [24]. To address the role of
the MAPK cascade in regulating MMP-26 expression by
GnRH I and GnRH II, we examined the phosphorylation
of JNK and ERK1/2 in B6Tert-1 cells treated with
GnRH I or GnRH II for 0, 5, 10 and 30 minutes. As
shown in Figure 4A, addition of 100 nM of GnRH I or
GnRH II resulted in a transient activation of JNK at 5
min or 10 min, respectively (Figure 4A). However, the
addition of both GnRH I and GnRH II had no effects
on ERK1/2 activity in B6Tert-1 cells (Figure 4A).
To further clarify the involvement of JNK and ERK1/2
in GnRH-induced MMP-26 expression, B6Tert-1 cells
were cultured with GnRH I or GnRH II in the absence
or presence of the JNK inhibitor (SP600125; 10 μM) or
ERK1/2 inhibitor (PD98059; 10 μM). SP600125, but not
PD98059, significantly blocked MMP-26 induction (Fig-
ure 4B). These data indicate that stimulation of MMP-
26 expression by GnRH I and II requires the activation
of JNK, but not ERK1/2 signaling molecules.
Regulatory effects of GnRH I and GnRH II on MMP-26
expression in primary cultured CTBs
We further confirmed the regulatory effects of GnRH I
and GnRH II on MMP-26 expression using the primary
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Figure 2 Time-dependent effects of GnRH I and GnRH II on MMP-26 expression in B6Tert-1 cells. A and B, The expression of MMP-26
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bated with GnRH I and GnRH II at concentrations of
0.1-100 nM for 24 h. A significant increase in MMP-26
mRNA levels was only observed in trophoblast cultured
i nt h ep r e s e n c eo fh i g h e rc o n c e n t r a t i o n so ft h e s et w o
hormones (1-100 nM) (Figure 5A). GnRH II at a con-
centration of 100 nM induced the maximal increase in
MMP-26 expression (Figure 5A).
To further determine the signaling mediators involved
in GnRH-induced MMP-26 expression, CTB cells were
cultured with 100 nM GnRH I and II in the presence of
10 μM SP600125 or PD98059. As shown in Figure 5B,
SP600125 inhibited the stimulatory effects of GnRH I
and GnRH II on MMP-26 mRNA levels, whereas
PD98059 had no effects on MMP-26 expression.
Discussion
MMP-26 is a recently discovered and only partially
characterized human proteinase [4-6]. Unlike all other
MMPs, the Mmp-26 gene does not exist in the murine
genome [4-6]. Besides its extensive distribution in can-
cer cells of epithelial origin [8], MMP-26 is also
restricted in human placenta and uterus, but nor in
other normal tissues [4,6]. Previous studies showed its
intensive expression in human trophoblasts in vivo and
invasive-promoting effect on trophoblast cells in vitro
[7,12], suggesting the unique role of MMP-26 in tropho-
blast invasion at the feto-maternal interface. However,
the regulation of MMP-26 expression in trophoblast
cells remains to be determined. In this study, we utilized
human trophoblast-like cell line, B6Tert-1, to show that
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Figure 3 Different dosage effects of GnRH I and GnRH II on MMP-26 expression in B6Tert-1 cells. A and B, The expression of MMP-26
mRNA (A) and protein (B) in B6Ter-1 cells cultured with increasing concentrations of GnRH I (0, 1, 10, 100 nM or 1 μM) for 24 h. C and D, The
expression of MMP-26 mRNA (C) and protein (D) in B6Ter-1 cells cultured with increasing concentrations of GnRH II (0, 1, 10, 100 nM or 1 μM)
for 24 h. Levels of mRNA for MMP-26 in each sample were normalized to the corresponding GAPDH. Levels of protein for MMP-26 were
normalized to the corresponding b-actin. The results derived from both these analyses as well as those from at least three other sets of
experiments were standardized to the untreated control and are represented (mean ± SEM; n ≥ 3) in the bar graphs (*, P < 0.05 vs. untreated
control).
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Page 6 of 101) both GnRH I and GnRH II could up-regulate MMP-
26 expression, 2) GnRH I and GnRH II had differential
effects on MMP-26 expression, and 3) GnRH I and II-
induced MMP-26 expression was mediated by JNK, but
not ERK1/2 signaling pathway.
The B6Tert-1 cell line is an immortalized cytotropho-
blast-like cell line developed from normal human pla-
cental villi during the first trimester. These cells are
transfected with human telomerase catalytic subunit
gene (htert) and thus maintain reconstituted telomerase
activity [18]. B6Tert-1 cells exhibit the characteristics of
normal EVTs by producing various biomarkers includ-
ing CK8, HLA-G, integrin a1 and integrin b1 [18]. They
also exhibit the ability to invade matrix and express pro-
teinase genes including MMP-2, MMP-9, MMP-14,
TIMP-1, TIMP-2 and TIMP-3, which are important
properties of EVTs [18]. In this study, we further
demonstrated that the expression of MMP-26 in
Figure 4 Involvement of JNK activity in GnRH I and II-induced MMP-26 production. A, B6Tert-1 cells were stimulated with GnRH I or GnRH
II (100 nM) for 5, 10 and 30 min, or the cells were left untreated as a control. Phosphorylation of ERK1/2 or JNK and the total amount of ERK1/2
or JNK were determined by Western blotting analyses. B. Following 30-minute pretreatment with PD98059 (10 μM, ERK1/2 inhibitor) or SP600125
(10 μM, JNK inhibitor), B6Tert-1 cells were treated with GnRH I or GnRH II (100 nM) for 24 h and the protein levels of MMP-26 analyzed by
Western blotting analyses. Levels of protein for MMP-26 were normalized to the corresponding b-actin. The results derived from both these
analyses as well as those from at least three other sets of experiments were standardized to the untreated control and are represented (mean ±
SEM; n ≥ 3) in the bar graphs (*, P < 0.05 vs. bar a; #, P < 0.05 vs. bar b; &, P < 0.05 vs. bar c).
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Figure 5 Regulatory effects of GnRH I and GnRH II on MMP-26 expression in primary cultured CTB cells. A, The expression of MMP-26
mRNA in CTB cells cultured with GnRH I (gray) or GnRH II (black) at concentrations of 0.1, 1, 10 and 100 nM for 24 h. B, Following 30-minute
pretreatment with PD98059 (10 μM, ERK1/2 inhibitor) or SP600125 (10 μM, JNK inhibitor), CTB cells were incubated with GnRH I (gray) or GnRH II
(black) at concentrations of 100 nM for 24 h and the mRNA levels of MMP-26 analyzed by Real-time PCR. Levels of mRNA for MMP-26 in each
sample were normalized to the corresponding GAPDH. The results derived from both these analyses as well as those from at least three other
sets of experiments were standardized to the untreated control and are represented (mean ± SEM; n ≥ 3) in the bar graphs (*, P < 0.05 vs.
untreated control).
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Page 7 of 10B6Tert-1 cells was comparable to that in the primary
CTB cells at early gestation. The invasiveness of B6Tert-
1 cells was regulated by paracrine and/or autocrine fac-
tors such as EGF and transforming growth factor b [18].
Here we showed that the invasive ability of B6Tert-1
cells was increased by GnRH I and GnRH II. This
observation is also consistent with our previous report
that GnRH I and GnRH II stimulated the invasiveness
of primary EVT cells [23]. Our data and other groups’
studies strongly suggest that the B6Tert-1 cell line is a
valuable in vitro cellular model for the investigation of
trophoblast-like/trophoblast cell behaviors [25,26]. In
the present study, we utilized B6Tert-1 cells to deter-
mine the regulatory mechanism of GnRHs on MMP-26
expression in human trophoblast-like/trophoblast cells.
The classical mammalian GnRH (GnRH I) is a deca-
peptide that is well-known for its role in regulating the
release of gonadotropins from the pituitary [27]. Evi-
dence shows that in addition to its classical endocrine
functions, GnRH I has direct regulatory actions on the
development and function of gonads and other repro-
ductive tissues such as the ovary, endometrium and pla-
centa [16,17,27-29]. A distinct gene encoding a second
form of GnRH, termed GnRH II, that is expressed in
human extrapituitary tissues [30], has been shown to
imitate the paracrine/autocrine function of GnRH I in
extrapituitary compartments [16,17,27-29]. Recent stu-
dies demonstrated that GnRH I and GnRH II promoted
the invasive capacity of human trophoblasts by regulat-
ing MMP-2, MMP-9/TIMP-1 and uPA/PAI protease
systems [16,17,23]. Consistent with these findings, our
present work indicated that both GnRH I and GnRH II
were capable of increasing the mRNA and protein levels
of MMP-26 in trophoblast-like/trophoblast cells. In
addition to its direct proteolytic action on ECM sub-
strates, MMP-26 has also been reported to be an activa-
tor of proMMP-9 in prostate cancer cells and correlated
to MMP-9 activity in esophageal carcinoma [10,31].
Considering the similar expression patterns between
MMP-26 and MMP-9 in trophoblasts during early
gestation [7,11], GnRH-induced MMP-26 production
may, at least in part, participate in proteolysis of the
ECM through activating the latent form of MMP-9. The
coordinate induction of MMP-2, MMP-9 and MMP-26
b yG n R H ss u g g e s t st h a tt h e s ee n z y m e sp o s s i b l ye l i c i t
their functions as components of a proteolytic cascade
in trophoblasts.
Although GnRH II is capable of mimicking the biolo-
gical actions of GnRH I in extrapituitary tissues, evi-
dence shows differential effects of these two hormones.
For instance, GnRH II exhibited more potent anti-prolif-
erative effects than an equimolar dose of GnRH I in
human endometrial and ovarian cancer cells [32]. In
human placenta, GnRH I was more effective than GnRH
II on hCG synthesis and secretion [33], while GnRH II
appeared to be more potent than GnRH I in stimulating
leptin secretion [34]. Recently, Chou et al. demonstrated
that GnRH II was capable of eliciting its regulatory
effects on MMP/TIMP systems at lower hormone con-
centrations than GnRH I in human EVTs [17]. In this
study, our data showed that the time course of the sti-
mulatory effect of GnRH II on MMP-26 expression was
earlier than that of GnRH I. In addition, GnRH I and
GnRH II had different dosage effects on MMP-26
expression in B6tert-1 cells. These differential actions of
GnRH I and GnRH II in regulating MMP-26 expression
might be explained by different degradation pathways
[35], different signaling cascades [23], different receptor
affinities [36] or even different types of GnRH receptor
[17,23].
It has been well established in gonadotropic cells that
the binding of GnRH with its receptor activates MAPK
cascades, leading to phosphorylation of ERK1/2 and
JNK [37]. This process is an important link for the
transmission of GnRH signals from the cell surface to
the nucleus [37]. MAPK also has been shown to mediate
the action of GnRH in human trophoblast cells [24]. In
the present study, we demonstrated the rapid and tran-
sient activation of JNK by GnRH I and GnRH II in
B6Tert-1 cells. GnRH I and II-induced MMP-26 expres-
sion was blocked by specific inhibition of JNK, but not
ERK1/2 in B6Tert-1 and primary CTB cells. JNK signal-
ing has been shown to be involved in the production of
various MMPs that promote invasiveness and migration
of cancer cells [38-40]. A recent study showed that JNK,
but neither ERK1/2 nor p38 MAPK, was critical for
GnRH-mediated production of MMP-2 and MMP-9 in
human ovarian cancer cells [41]. In agreement with
these observations, our data suggests that JNK, but not
ERK1/2, may play a central role in mediating the effects
of GnRHs on MMP-26 production in human tropho-
blast-like/trophoblast cells.
Conclusions
In summary, this is the first report in our knowledge to
demonstrate that GnRH I and GnRH II up-regulate the
expression of MMP-26 through the JNK pathway in
human trophoblast-like/trophoblast cells. These findings
provide the basis for further studies into the regulatory
mechanism of MMP-26 expression and its biological
function in human trophoblasts during implantation and
placentation.
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